KRAS and colorectal carcinoma: Mutations in the Kirsten rat sarcoma (KRAS) viral oncogene have been reported to be present in 30–40% of CRC patients and to correlate with clinical resistance to anti-EGFR drugs in metastatic CRCs [4–6].